Roche has launched two new decision support tools aimed at matching patients to the most appropriate clinical trial, and helping clinicians search for relevant medical literature.<
A combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage trial in untreated but advanced kidney cancer.